Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.41 |
| ▸ | CBFB | Q13951 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204601 | 0.77 | ALDH1A1 (0.44) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL9133922 | 0.74 | MAPT (0.60) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL224905 | 0.74 | APP (0.48) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL6740524 | 0.74 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL6740529 | 0.74 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL1145924 | 0.71 | HRH3 (0.50) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL3190275 | 0.70 | — | — | |
| SCHEMBL10577638 | 0.69 | KIF11 (0.44) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL6742050 | 0.69 | ALDH1A1 (0.38) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL12158655 | 0.69 | ALDH1A1 (0.38) | ALDH1A1GAAMAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014690-A1 | Macrolides with activity against methicillin-resistant staphylococcus aureus | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353914-A2 | THERAPEUTIC CHROMONE COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353913-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| US-20030162729-A1 | Macrolides with activity against methicillin-resistant staphylococcus aureus | ABBOTT LABORATORIES | 2003-08-28 | — | — | US | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014690-A1 | Macrolides with activity against methicillin-resistant staphylococcus aureus | HDAC1, HDAC11, STS | ALDH1A1 1160/4885GAA 510/4885MAPT 4721/4885 |
| US-20030162729-A1 | Macrolides with activity against methicillin-resistant staphylococcus aureus | HDAC1, HDAC11, STS | ALDH1A1 1160/4885GAA 510/4885MAPT 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.